Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
Abstract Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the lysosomal enzyme, α‐galactosidase. Gb3 deposits activate immune‐mediated systemic inflammation, ultimately leading to life‐threatening co...
Saved in:
Main Authors: | Li Fu (Author), Sylwia Wasiak (Author), Laura M. Tsujikawa (Author), Brooke D. Rakai (Author), Stephanie C. Stotz (Author), Norman C. W. Wong (Author), Jan O. Johansson (Author), Michael Sweeney (Author), Connie M. Mohan (Author), Aneal Khan (Author), Ewelina Kulikowski (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
by: Sylwia Wasiak, et al.
Published: (2020) -
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
by: Ewelina Kulikowski, et al.
Published: (2018) -
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
by: Peter P. Toth, et al.
Published: (2022) -
Doença de Fabry Fabry disease
by: Paula Boggio, et al.
Published: (2009) -
Exploring the therapeutic potential of apabetalone in diabetic kidney disease: Bridging preclinical findings with clinical translation
by: Honglian Luo, et al.
Published: (2024)